TY - JOUR
T1 - Fatal disseminated mucormycosis associated with COVID-19
AU - Horiguchi, Tomoya
AU - Tsukamoto, Tetsuya
AU - Toyama, Yoko
AU - Sasaki, Toshiharu
AU - Nakamura, Tomoyuki
AU - Sakurai, Aki
AU - Kuriyama, Naohide
AU - Komatsu, Satoshi
AU - Shigeyasu, Yoshiko
AU - Ina, Takuma
AU - Sakurai, Eiko
AU - Nakajima, Noriko
AU - Tsuchimori, Arisa
AU - Yamada, Seiji
AU - Suzuki, Tadaki
AU - Imaizumi, Kazuyoshi
N1 - Publisher Copyright:
© 2022 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology.
PY - 2022/3
Y1 - 2022/3
N2 - Secondary fungal infections are a critical problem that accompany immunosuppressive therapy for severe coronavirus disease 2019 (COVID-19). We report a fatal case of COVID-19 with disseminated mucormycosis diagnosed during autopsy. A 58-year-old man with diabetes was hospitalized for severe COVID-19 and treated with remdesivir, systemic steroids and tocilizumab. Following treatment, he was provided extracorporeal membrane oxygenation support. However, he died of multiple organ failure accompanied by pulmonary and kidney infarction, as revealed by computed tomography. Autopsy revealed that the infarction was caused by thromboangiitis due to mucormycosis in the brain, lungs, heart, liver and kidneys. Therefore, the diagnosis of disseminated mucormycosis was established. Disseminated mucormycosis is a rare complication of COVID-19. Although its early diagnosis is difficult, the disease progresses rapidly. Hence, we propose that immunosuppressive treatment for COVID-19 should be administered with caution considering the risk of developing severe opportunistic infections, such as mucormycosis.
AB - Secondary fungal infections are a critical problem that accompany immunosuppressive therapy for severe coronavirus disease 2019 (COVID-19). We report a fatal case of COVID-19 with disseminated mucormycosis diagnosed during autopsy. A 58-year-old man with diabetes was hospitalized for severe COVID-19 and treated with remdesivir, systemic steroids and tocilizumab. Following treatment, he was provided extracorporeal membrane oxygenation support. However, he died of multiple organ failure accompanied by pulmonary and kidney infarction, as revealed by computed tomography. Autopsy revealed that the infarction was caused by thromboangiitis due to mucormycosis in the brain, lungs, heart, liver and kidneys. Therefore, the diagnosis of disseminated mucormycosis was established. Disseminated mucormycosis is a rare complication of COVID-19. Although its early diagnosis is difficult, the disease progresses rapidly. Hence, we propose that immunosuppressive treatment for COVID-19 should be administered with caution considering the risk of developing severe opportunistic infections, such as mucormycosis.
UR - http://www.scopus.com/inward/record.url?scp=85125141756&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125141756&partnerID=8YFLogxK
U2 - 10.1002/rcr2.912
DO - 10.1002/rcr2.912
M3 - Article
AN - SCOPUS:85125141756
SN - 2051-3380
VL - 10
JO - Respirology Case Reports
JF - Respirology Case Reports
IS - 3
M1 - e0912
ER -
